Share This Page
Suppliers and packagers for ridaura
✉ Email this page to a colleague
ridaura
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Legacy Pharma | RIDAURA | auranofin | CAPSULE;ORAL | 018689 | NDA | Sebela Pharmaceuticals Inc. | 54766-093-06 | 60 CAPSULE in 1 BOTTLE (54766-093-06) | 2016-12-15 |
| Legacy Pharma | RIDAURA | auranofin | CAPSULE;ORAL | 018689 | NDA AUTHORIZED GENERIC | Coral Way Pharma, LLC | 85437-093-06 | 60 CAPSULE in 1 BOTTLE (85437-093-06) | 2025-10-29 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for ridaura
Who Manufactures Ridaura (Auranofin): Active Ingredient and Brand-Given Supply Chain
Ridaura is the brand name of auranofin, an oral disease-modifying therapy for rheumatoid arthritis. The drug is supplied globally through branded-label distribution and generic sourcing of auranofin API and finished dosage units. Public-facing supplier disclosure for the exact upstream manufacturers of “Ridaura” in every market is limited, but the active ingredient and the finished dosage are consistently supplied by established generic and API manufacturers in the worldwide auranofin supply base.
What active ingredient supplier base feeds Ridaura?
Ridaura uses auranofin. In practice, branded versions and generics draw from the same global API network, where auranofin is manufactured under contract by a small set of known chemical suppliers and converted into tablets/capsules by finished-dose manufacturers. For business diligence, the practical supplier set is the set of auranofin API manufacturers listed in regulatory dossiers and the set of finished-dose manufacturers listed for the marketed product in each country.
Because you asked for “Suppliers,” the relevant evidence is controlled by regulatory filings and label listings by country. Below is the supplier information that is directly tied to the marketed product “Ridaura” and its active ingredient auranofin in the U.S. label context.
Which companies are named on the U.S. Ridaura label supply chain?
U.S. product information for Ridaura (auranofin) identifies the marketed product distributor/labeler and the manufacturer responsible for the dosage form, rather than the raw API source. In U.S. FDA labeling, the “manufacturer/distributor” field is the most reliable public supplier anchor for the marketed product.
Ridaura (auranofin) U.S. label supply entities
- Labeler/Distributor: listed on the package insert under “Manufactured for” / “Distributed by” fields (country label dependent).
- Manufacturer of finished dosage form: listed on the package insert under “Manufactured by” (country label dependent).
The exact named entities depend on the current label revision for the specific NDC. This is why Ridaura supplier diligence is usually done by mapping:
1) NDC to labeler/manufacturer
2) labeler/manufacturer to the site(s)
3) site(s) to GMP inspections and then to upstream API sourcing
Where do Ridaura manufacturers typically source auranofin API?
Auranofin API is a specialty organogold compound. The supplier pool typically includes:
- Chemical API manufacturers making auranofin under GMP
- Contract manufacturing organizations that compress tablets and package finished product
- Labeler-distributors that market Ridaura (or Ridaura equivalents)
From a patent and competitive intelligence perspective, the most actionable supplier map is:
- API sites (auranofin production)
- Finished-dose sites (tablet/packaging)
- Commercial distributors (NDC labeler)
Public sources outside regulatory submissions seldom disclose the upstream API site for a specific branded NDC.
How to identify the actual Ridaura supplier for a given market (commercial diligence checklist)
Use this deterministic sequence to avoid guessing: 1) Extract the NDC from the specific bottle/box 2) Pull the corresponding FDA label entry for that NDC 3) Record:
- “Manufactured for” (labeler)
- “Manufactured by” (finished-dose site)
- package insert revision date (locks supplier identities to a label epoch) 4) Cross-check the manufacturer site against:
- recent FDA inspection outcomes (Form 483 outcomes and Establishment Inspection Reports where available)
- GMP compliance history 5) If needed for full upstream mapping, trace to:
- DMF references in ANDA/abbreviated filings (where publicly available)
- or supplier references in regulatory dossiers in the target country
Key Takeaways
- Ridaura is auranofin; supplier disclosure for the exact API site is not typically stated on public brand labeling.
- For actionable supplier identification, the most reliable public anchor is the finished-dose manufacturer and labeler listed on the current NDC-specific package insert.
- Best practice supplier mapping for Ridaura is NDC-driven: NDC -> labeler/manufacturer -> site -> GMP history -> upstream API via regulatory trace where available.
FAQs
1) Is Ridaura sourced from the same supply base as generic auranofin?
Yes. Commercial supply for auranofin in tablets generally draws from the same upstream auranofin API market and overlapping finished-dose manufacturing capacity. The branded label identifies the finished-dose manufacturer and labeler, not necessarily the same API site across batches.
2) Can I find the exact API supplier for Ridaura from the package insert?
Usually no. U.S. package inserts typically list the finished-dose manufacturer and labeler/distributor, while upstream API manufacturing sites are generally not disclosed.
3) What is the most reliable way to identify Ridaura’s finished-dose supplier?
Use the NDC on the specific product and match it to the corresponding FDA label entry to capture the “Manufactured by” and “Manufactured for/Distributed by” names.
4) Why do Ridaura suppliers change over time?
Changes occur when the labeler switches contract manufacturers, manufacturing sites, packaging suppliers, or when label revisions update distributor/manufacturer information for compliance and logistics.
5) What is the supplier focus for R&D or investment diligence?
Prioritize finished-dose GMP site (manufacturing/packaging) and then trace API GMP capability via regulatory dossiers and supplier listings for auranofin.
References
[1] U.S. Food and Drug Administration. Ridaura (auranofin) Prescribing Information (labeling and manufacturer/distributor fields). FDA label database.
[2] National Library of Medicine. Drugs@FDA entry for Ridaura (auranofin) (NDC-linked label and manufacturer/distributor information).
More… ↓
